Company intelligence / Profile preview
Guangshengtang
Fujian, Chinacosunter.com ↗
- Ownership
- Private
- Development stage
- Other
01
Overview
Guangshengtang's lead program, nerecovir (GST-HG141), for chronic hepatitis B, has completed a positive Phase II trial showing significant inhibition of hepatitis B DNA and pgRNA and has been designated for breakthrough therapy; several additional drug candidates targeting hepatitis B and related liver diseases are in clinical and preclinical stages[1].
- Therapeutic areas
- OncologyGastroenterologyInfectious Diseases
- Modalities
- Small moleculeBiologic
- Industry
- Biotech
02
Drug pipeline
1 assetBeyond the preview
Go deeper on Guangshengtang.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Guangshengtang.